Intra-Cellular Therapies Inc (BSP:I2TC34)
R$ 84.24 0 (0%) Market Cap: 8.93 Bil Enterprise Value: 2.80 Bil PE Ratio: 0 PB Ratio: 7.86 GF Score: 31/100

Intra-Cellular Therapies Inc at Goldman Sachs Healthcare Conference Transcript

Jun 12, 2023 / 09:00PM GMT
Corinne Jenkins
Goldman Sachs Group, Inc., Research Division - VP

All right. Well, we're getting started. Great to see you. Thanks, everyone, for joining us today, and thanks for the team from Intra-Cellular for joining us as well. Maybe just we could start with a brief overview. If you could -- brief overview on where the company stands today and what you see as key value drivers over the next 12 to 24 months?

Sharon Mates
Intra-Cellular Therapies, Inc. - Co-Founder, Chairman, CEO & President

Right, so thanks. It's great to be here. Although it's nice and warm in here, so that's really terrific as opposed to out there where it's pretty cold. So let me just give you an overview on the company. We started the company in 2002. And what's great today, first of all, is our first product, CAPLYTA, which first got approval in 2019 for the treatment of schizophrenia in adults. Fast forward to December 2021 and received a label expansion for the treatment of bipolar depression.

And really, in the past year, since that launch for bipolar depression, we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot